TTC27: A Promising Drug Target and Biomarker for Tetratricopeptide Repeat Domain-Controlled Protein 27

Target Name: TTC27

NCBI ID: G55622

TTC27

TTC27: A Promising Drug Target and Biomarker for Tetratricopeptide Repeat Domain-Controlled Protein 27

Abstract:

Tetratricopeptide repeat domain (TTC) is a conserved protein domain that can be found in various organisms, including humans. It is characterized by a specific sequence that is responsible for the self-assembly of the protein into a monomeric form. TTC has been implicated in various biological processes, including cell signaling, DNA replication, and protein-protein interactions. In this article, we discuss TTC27, a variant of TTC that has potential as a drug target and biomarker. We review the current research on TTC27, including its function, biochemical properties, and potential as a drug target.

Introduction:

Tetratricopeptide repeat domain (TTC) is a conserved protein domain that is characterized by a specific sequence that is responsible for the self-assembly of the protein into a monomeric form. This domain is found in various organisms, including humans, and has been implicated in various biological processes, including cell signaling, DNA replication, and protein-protein interactions.

TTC has been identified as a potential drug target due to its unique structure and its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Several studies have shown that TTC can be targeted with small molecules and antibodies, leading to the development of new therapeutic approaches.

TTC27: A variant of TTC with potential as a drug target and biomarker

TTC27 is a variant of TTC that has been identified as a potential drug target due to its unique structure and its involvement in various diseases. It is characterized by a specific sequence that is responsible for the self-assembly of the protein into a monomeric form.

The TTC27 protein is a 14-kDa protein that is expressed in various tissues and cells in the body. It is characterized by a unique N-terminus that consists of a 27 amino acid repeat, which is responsible for the self-assembly of the protein into a monomeric form.

Several studies have shown that TTC27 can be targeted with small molecules and antibodies, leading to the development of new therapeutic approaches. For example, a small molecule inhibitor that targets the TTC27 N-terminus has been shown to inhibit the growth of cancer cells, including those derived from breast, lung, and ovarian cancers.

In addition, TTC27 has also been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that TTC27 is involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Furthermore, TTC27 has also been shown to be involved in the development of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

Conclusion:

TTC27 is a variant of TTC that has potential as a drug target and biomarker due to its unique structure and its involvement in various diseases. The development of new therapeutic approaches for TTC27 may lead to the development of new treatments for a variety of diseases. Further research is needed to fully understand the function of TTC27 and its potential as a drug target.

Protein Name: Tetratricopeptide Repeat Domain 27

The "TTC27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets